Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gozanertinib in Head and Neck and Lung Cancer
NCT03246854Phase 1Terminated
- Sponsor
- National Health Research Institutes
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gozanertinib in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), sponsored by National Health Research Institutes. Primary endpoints: Maximum Tolerated Dose up to 22 months, Area Under the Plasma Concentration-Time Curve at Cycle 2 and 2 more. Started Jul 2017; status: terminated.
02
Drugs
gozanertinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03246854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246854.